CTLA4 and neuroblastoma: Since tumor burden can affect the response to immunotherapy in murine models,43 we set up an anti-CTLA4 failure model where anti-CTLA4 was administered on a schedule that was insufficient to inhibit the growth of idMMR neuroblastoma tumors.